Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Ruxolitinib
Related studies linked through entity extraction aliases.
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
- Status
- COMPLETED
- Phase
- PHASE2
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
- Status
- TERMINATED
- Phase
- PHASE1
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Ruxolitinib in Operable Head and Neck Cancer
- Status
- TERMINATED
- Phase
- PHASE2
An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
- Status
- COMPLETED
- Phase
- PHASE2
Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
- Status
- TERMINATED
- Phase
- PHASE2
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
- Status
- COMPLETED
- Phase
- PHASE3
A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ruxolitinib Phosphate in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2